Tactile Systems Technology Inc (TCMD) News & EventsTCMDNews & EventsTactile Systems Technology Inc

Tactile Medical Q2 Revenue $85.7M Beats Expectations

Reports Q2 revenue $85.7M, consensus $85.52M. "We are encouraged by our strong momentum in the second quarter. We delivered solid revenue growth, expanded gross margin, and generated meaningful adjusted EBITDA, underscoring the strength of our business model and our team's disciplined execution," said Sheri Dodd, Chief Executive Officer of Tactile Medical. "Our core lymphedema business remains healthy and our view of the long-term opportunity for AffloVest to be a leading high frequency chest wall oscillation technology therapy is unchanged despite the impact of a temporary inventory management dynamic related to the launch of our next-generation AffloVest system during the quarter."

Company Updates 2026 Revenue Outlook to $368 Million

Consensus $360.52M. Backs FY26 adjusted EBITDA view $49M-$51M. The company said, "The Company is updating its 2026 financial outlook and now expects full year 2026 total revenue in the range of $360 million to $368 million, representing growth of approximately 9% to 12% year-over-year, compared to total revenue of $329.5 million in 2025. The Company's prior 2026 guidance expectation was total revenue in the range of $357 million to $365 million, representing growth of approximately 8% to 11% year-over-year. The Company continues to expect full year 2026 adjusted EBITDA in the range of $49 million to $51 million, compared to adjusted EBITDA of $44.8 million in 2025."

Tactile Medical Q1 Revenue $75.27M, Exceeds Expectations

Reports Q1 revenue $75.27M, consensus $70.57M. "We delivered a strong start to 2026, with first quarter revenue growth of 23% year-over-year driven by disciplined execution of our strategic priorities," said Sheri Dodd, Chief Executive Officer of Tactile Medical. "Performance in the quarter was broad-based and reflected the strength and durability of our go-to-market strategy, including increased productivity from a fully resourced sales organization, growing access to advanced therapy under the NCD, and continued momentum across both lymphedema and airway clearance. Importantly, this top line strength translated into meaningful expansion in gross margin and adjusted EBITDA, underscoring the operating leverage in our model."